Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination

  • Julien Favresse
    Correspondence
    Corresponding author.
    Affiliations
    University of Namur, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Rue Saint-Luc, 8 – 5004, Bouge, Namur, Belgium

    Clinique Saint-Luc Bouge, Department of Laboratory Medicine, Bouge, Belgium
    Search for articles by this author
  • Jonathan Douxfils
    Affiliations
    University of Namur, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Rue Saint-Luc, 8 – 5004, Bouge, Namur, Belgium

    QUALIblood s.a., Namur, Belgium
    Search for articles by this author

      Highlights

      • All participants had high antibody titers after 3 months with the mRNA-BNT162b2 vaccine.
      • Nevertheless, a highly significative antibody decrease was observed at 3 months, only when a dilution factor was applied.
      • Non saturated quantitative signals are needed to study the real kinetics of antibodies.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tré-Hardy M.
        • Cupaiolo R.
        • Wilmet A.
        • Beukinga I.
        • Blairon L.
        Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.
        J Infect. 2021; (2021-06-01)
        • Favresse J.
        • Bayart J.L.
        • Mullier F.
        • Dogne J.M.
        • Closset M.
        • Douxfils J.
        Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
        Clin Microbiol Infect. 2021 May 8; (PubMed PMID:33975007. Pubmed Central PMCID: PMC8106520. Epub 2021/05/12)
      1. Favresse J., Bayart J.-.L., Mullier F., Elsen M., Eucher C., Eechhoudt S.V., et al. Antibody titers decline 3-month post-vaccination with BNT612b2. 202. Emerg Microbes Infect. 2021 Jul 7;1-8. doi:10.1080/22221751.2021.1953403. Online ahead of print.

        • Doria-Rose N.
        • Suthar M.S.
        • Makowski M.
        • O'Connell S.
        • McDermott A.B.
        • Flach B.
        • et al.
        Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19.
        N Engl J Med. 2021 Apr 6; (PubMed PMID:33822494. Epub 2021/04/07)
        • Widge A.T.
        • Rouphael N.G.
        • Jackson L.A.
        • Anderson E.J.
        • Roberts P.C.
        • Makhene M.
        • et al.
        Durability of responses after SARS-CoV-2 mRNA-1273 vaccination.
        N Engl J Med. 2021 Jan 7; 384 (PubMed PMID:33270381. Pubmed Central PMCID: PMC7727324. Epub 2020/12/04): 80-82
        • Manisty C.
        • Otter A.D.
        • Treibel T.A.
        • McKnight A.
        • Altmann D.M.
        • Brooks T.
        • et al.
        Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
        Lancet. 2021 Mar 20; 397 (PubMed PMID:33640038. Pubmed Central PMCID: PMC7972310. Epub 2021/03/01): 1057-1058
        • Salvagno G.L.
        • Henry B.M.
        • di Piazza G.
        • Pighi L.
        • De Nitto S.
        • Bragantini D.
        • et al.
        Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination.
        Diagnostics. 2021; 11 (PubMed PMID: doi): 832https://doi.org/10.3390/diagnostics11050832
        • Prendecki M.
        • Clarke C.
        • Brown J.
        • Cox A.
        • Gleeson S.
        • Guckian M.
        • et al.
        Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
        Lancet. 2021 Mar 27; 397 (PubMed PMID:33640037. Pubmed Central PMCID: PMC7993933. Epub 2021/03/01): 1178-1181
        • Capetti A.F.
        • Stangalini C.A.
        • Borgonovo F.
        • Mileto D.
        • Oreni L.
        • Dedivitiis G.
        • et al.
        Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine.
        Clin Infect Dis. 2021 Mar 6; (PubMed PMID:33693610. Pubmed Central PMCID: PMC7989538. Epub 2021/03/12)
        • Tre-Hardy M.
        • Wilmet A.
        • Beukinga I.
        • Dogne J.M.
        • Douxfils J.
        • Blairon L.
        Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody.
        Clin Chem Lab Med: CCLM /FESCC. 2020 Jul 28; 58 (PubMed PMID:32447328. Epub 2020/05/25): 1357-1364